Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

• ClinicalTrials.gov Identifier: NCT00074165
• Recruitment Status: Terminated
• First Posted: December 11, 2003
• Results First Posted: November 16, 2011
• Last Update Posted: April 21, 2017
• Sponsor: OHSU Knight Cancer Institute
• Collaborator: National Cancer Institute (NCI)
• Information provided by (Responsible Party): Edward Neuwelt, OHSU Knight Cancer Institute

Study Description

Brief Summary:

RATIONALE: Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy, such as carboplatin, cyclophosphamide, etoposide, etoposide phosphate, and cytarabine, use different ways to stop cancer cells from dividing so they stop growing or die. Osmotic blood-brain barrier disruption uses certain drugs to open the blood vessels around the brain and allow anticancer substances to be delivered directly to the brain tumor. Chemoprotective drugs such as sodium thiosulfate may protect normal cells from the side effects of carboplatin-based chemotherapy. Combining rituximab with chemotherapy given with osmotic blood-brain barrier disruption plus sodium thiosulfate may kill more cancer cells.

PURPOSE: Phase II trial to study the effectiveness of combining rituximab with combination chemotherapy given with osmotic blood-brain barrier disruption plus sodium thiosulfate in treating patients who have refractory or recurrent primary CNS lymphoma.

Condition or disease	Intervention/treatment	Phase
Brain and Central Nervous System Tumors; Drug/Agent Toxicity by Tissue/Organ; Lymphoma; Thrombocytopenia	Drug: Rituxan; Drug: Cyclophosphamide; Drug: Etoposide; Drug: Etoposide phosphate; Drug: Carboplatin; Drug: Sodium thiosulfate; Drug: Neupogen; Drug: Neulasta; Drug: Cytarabine	Phase 2

Detailed Description:

OBJECTIVES:

Primary

• Determine the efficacy of rituximab, carboplatin, cyclophosphamide, etoposide or etoposide phosphate and cytarabine administered in conjunction with osmotic blood-brain barrier disruption and high-dose sodium thiosulfate, in terms of complete response rate, in patients with refractory or recurrent primary CNS lymphoma.

Secondary

• Determine the overall survival and 2-year progression-free survival of patients treated with this regimen.
• Determine the quality of life and cognitive function of patients treated with this regimen.
• Determine the neurotoxicity of this regimen in these patients.
• Determine the percentage of patients with ototoxicity over time after treatment with this regimen.
• Determine the effect of delayed administration of sodium thiosulfate on granulocyte and erythrocyte counts in these patients.

OUTLINE: This is a multicenter study.

Patients receive rituximab IV on day 1. On days 2 and 3, patients receive carboplatin intra-arterially over 10 minutes, cyclophosphamide IV over 10 minutes, and etoposide or etoposide phosphate IV over 10 minutes in conjunction with blood-brain barrier disruption. Patients also receive high-dose sodium thiosulfate IV over 15 minutes administered 4 and 8 hours after carboplatin on days 2 and 3 and intraventricular or intrathecal cytarabine on day 14. Beginning 48 hours after the last dose of chemotherapy, patients receive filgrastim (G-CSF)* subcutaneously (SC) daily for 7-10 days or until blood counts recover. Treatment repeats every 4 weeks for up to 12 courses.

NOTE: * Alternatively, patients may receive a single dose of pegfilgrastim SC, administered 48 hours after the completion of chemotherapy

Patients with intraocular lymphoma also receive methotrexate intravitreally twice weekly until the vitreous is clear of cells by slit lamp exam; once weekly for 1 month; and then monthly for 1 year.

Quality of life is assessed at baseline, every 3 months during treatment, within 30 days of final treatment, then every 6 months for 1 year, and then annually thereafter.

Patients are followed monthly for 3 months, every 2 months for 8 months, every 3 months for 1 year, and then every 6 months thereafter.

PROJECTED ACCRUAL: A total of 11-25 patients will be accrued for this study within 7-10 years.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 17 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase II Trial Involving Patients With Recurrent PCNSL Treated With Carboplatin/BBBD, by Adding Rituxan (Rituximab), An Anti CD-20 Antibody, To The Treatment Regimen
• Study Start Date: January 2003
• Actual Primary Completion Date: June 2010
• Actual Study Completion Date: December 2010

Arms and Interventions

Arm

Intervention/treatment

Experimental: All subjects

Drug: Rituxan; Total dose: 375mg/m2 infused IV; Every 4 weeks for up to one year.; Other Name: Rituximab; Drug: Cyclophosphamide; Dose 330mg/m2 x 2 days infused IV; Every 4 weeks for up to 1 year; Drug: Etoposide; Dose 200mg/m2 x 2 days infused IV; Every 4 weeks for up to one year. Etoposide phosphate may be given instead.; Drug: Etoposide phosphate; Dose 200mg/m2 infused IV x 2 days; Every 4 weeks for up to one year. Etoposide may be given instead.; Drug: Carboplatin; Dose: 200mg/m2 x 2 days infused IA with BBBD; Every 4 weeks for up to one year.; Drug: Sodium thiosulfate; Dose: 4 hrs post carboplatin = 20gm/m2; Dose: 8 hrs post carboplatin = 16gm/m2 Infused IV x 2 days; Other Name: STS; Drug: Neupogen; 48 hours after chemotherapy, QD x 7-10 days until WBC greater than 5000. Neulasta (Pegfilgrastim) may be given instead.; Other Names: G-CSF; filgrastim; Drug: Neulasta; Dose: 6mg, 24-72 hours after chemotherapy. Neupogen may be given instead.; Other Name: Pegfilgrastim; Drug: Cytarabine; Dose: 40mg on Day 14 following chemotherapy

Outcome Measures

Primary Outcome Measures :

1. Number of Participants With a Complete Response Rate to Chemotherapy Regimen Assessed by Radiographic Response at 2 Years. [ Time Frame: 2 years ]
   Per RECIST criteria (v1.1) and assessed by magnetic resonance imaging (MRI): Complete response (CR), Disappearance of all target lesions.

Secondary Outcome Measures :

1. Number of Participants With Overall Survival Assessed by Clinical and Radiographic Response [ Time Frame: 5 years ]
   Overall survival is measured from entry onto study until death from any cause or until death or progression of disease, respectively.
2. Progression-free Survival Assessed by Clinical and Radiographic Response From First Day of Treatment Until Tumor Progression [ Time Frame: 5 years ]
3. Quality of Life Assessed by EORTC QOL Before Treatment and Then Every 3 Months [ Time Frame: 5 years ]
4. Ototoxicity Assessed by Audiology Hearing Test Done Monthly During Treatment [ Time Frame: 2 years ]
5. Effect of Sodium Thiosulfate (STS) on Granulocytes and Erythrocytes Assessed by Complete Blood Count Lab Values Done Weekly During Treatment [ Time Frame: 2 years ]

Eligibility Criteria

• Ages Eligible for Study: 18 Months to 75 Years (Child, Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

INCLUSION CRITERIA:

• Signed informed consent form in accordance with institutional guidelines
• Histologically or cytologically confirmed primary CNS lymphoma documented by brain biopsy or cerebrospinal fluid or vitrectomy analysis
• CD20 positive disease
• Progressive or relapsed disease during or after completion of prior methotrexate-based chemotherapy
• Aged 18 months to 75 years
• Performance status ECOG 0-3 OR Karnofsky 30-100%
• Hematocrit at least 25% (transfusion or epoetin alfa allowed)
• Absolute granulocyte count at least 1,200/mm^3
• Platelet count at least 100,000/mm^3 OR at least lower limit of normal
• Bilirubin no greater than 2.0 times upper limit of normal
• Creatinine less than 1.8 mg/dL
• Calculated Creatinine clearance (CrCl) at least 50 mL/min
• Adequate cardiac function to tolerate general anesthesia
• Adequate pulmonary function to tolerate general anesthesia
• Available for follow-up for 1 year post therapy
• Fertile patients must use effective contraception for a minimum of 2 months before and during study participation

EXCLUSION CRITERIA:

• Radiographic signs of intra-cranial herniation and/or spinal block
• HIV positive
• Systemic lymphoma
• Positive serum HCG, pregnant or lactating
• Allergy to study agents
• Hepatitis B or hepatitis C positive

Contacts and Locations

Locations

United States, Ohio

Good Samaritan Hospital Cancer Treatment Center, Hatton Institute

Cincinnati, Ohio, United States, 45220

United States, Oregon

Knight Cancer Institute at Oregon Health and Science University

Portland, Oregon, United States, 97239-3098

Sponsors and Collaborators

OHSU Knight Cancer Institute

National Cancer Institute (NCI)

Investigators

• Principal Investigator: Edward A. Neuwelt, MD; OHSU Knight Cancer Institute

More Information

• Responsible Party: Edward Neuwelt, Professor, OHSU Knight Cancer Institute
• ClinicalTrials.gov Identifier: NCT00074165
• Obsolete Identifiers: NCT00261651
• Other Study ID Numbers: IRB00000641; 5R01CA137488-15 ( U.S. NIH Grant/Contract ); ONC-02059-LX ( Other Identifier: OHSU Knight Cancer Institute ); 641 ( Other Identifier: OHSU eIRB ); 7465 ( Other Identifier: OHSU IRB (discontinued number) ); OHSU-641 ( Other Identifier: OHSU IRB )
• First Posted: December 11, 2003
• Results First Posted: November 16, 2011
• Last Update Posted: April 21, 2017
• Last Verified: April 2017

Keywords provided by Edward Neuwelt, OHSU Knight Cancer Institute:

drug/agent toxicity by tissue/organ; thrombocytopenia; intraocular lymphoma; primary central nervous system non-Hodgkin lymphoma; primary central nervous system Hodgkin lymphoma

Additional relevant MeSH terms:

Lymphoma; Nervous System Neoplasms; Central Nervous System Neoplasms; Thrombocytopenia; Drug-Related Side Effects and Adverse Reactions; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Blood Platelet Disorders; Hematologic Diseases; Neoplasms by Site; Nervous System Diseases; Chemically-Induced Disorders; Cytarabine; Sodium thiosulfate; Cyclophosphamide; Rituximab; Carboplatin; Etoposide; Etoposide phosphate; Immunosuppressive Agents; Immunologic Factors; Physiological Effects of Drugs; Antirheumatic Agents; Antineoplastic Agents, Alkylating; Alkylating Agents; Molecular Mechanisms of Pharmacological Action